title: Processing of viral DNA ends channels the HIV-1 integration reaction to concerted integration.
abstract: Retroviral DNA made by reverse transcription is blunt-ended, and the viral integrase protein must remove two nucleotides from each 3' end prior to integration into chromosomal DNA. Under most reaction conditions for integration in vitro, the majority of the reaction products are "half-site" products that result from integration of only one viral DNA end into one strand of the target DNA. Preprocessed DNA substrates are more efficient substrates for half-site reactions than are blunt-ended substrates, which require the removal of two nucleotides prior to integration. In contrast, we find that blunt-ended DNA is a better substrate for the biologically relevant reaction of concerted integration of pairs of viral DNA ends. The reaction pathway is channeled to concerted integration, and half-site integration products are reduced with blunt-ended DNA substrate that must first be processed by integrase. In addition, the terminal nucleotide requirements for concerted integration are more stringent than for the half-site reaction. Longer DNA is more efficient for the concerted reaction than is shorter DNA that is capable of efficient half-site integration. This suggests that nonspecific interactions of integrase with viral DNA distant from the termini contribute to the assembly of a complex that is competent for concerted integration. Finally, differential effects of mutation of a residue in the C-terminal domain of integrase on concerted versus half-site integration implicate protein-protein interactions involving this domain as important for concerted integration.
authors.affiliation: Laboratory of Molecular Biology, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Robert
authors.initials: R
authors.lastname: Craigie
mesh_terms: D004247:DNA / Q000737:chemistry; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000378:metabolism; D019427:HIV Integrase / Q000737:chemistry; D015497:HIV-1 / Q000378:metabolism*; D008957:Models, Genetic; D009154:Mutation; D009690:Nucleic Acid Conformation; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D012190:Retroviridae / Q000235:genetics; D012492:Salts / Q000494:pharmacology; D016662:Virus Integration
chemical_list: D004279:DNA, Viral; D012492:Salts; D004247:DNA; D019427:HIV Integrase